VALNEVA SE EO -_15
Commented by André Will-Laudien on January 10th, 2022 | 10:22 CET
Tembo Gold, BioNTech, Valneva, MorphoSys - Turnaround or crash?
At the beginning of the year, there is much talk about the seemingly eternally running stock markets and the infinite wealth of those who have done everything right. Of course, shorting Tesla was a risk; it went wrong 85% of the time. However, since the "minutes" of the Federal Reserve, it is perhaps not a new short with the announcement. Because interest rates will probably have to rise once the tapering gets going. Incidentally, opinions are divided on the inflation trend: some banks estimate a 1 before the decimal point, others see a 5. So what now? Interest rates up mean problems for growth stocks; interest rates down could mean a continuation of the bull market. We take a look at interesting shares with their own stories.
Read
Commented by Nico Popp on January 7th, 2022 | 12:51 CET
BioNTech, XPhyto, Valneva: 3 stocks for next week?
Omicron is slowly but surely making its presence felt in Germany. After the holidays, when first there is less testing, and secondly the fax machines in German health offices are at a standstill, the official statistics are becoming a little more accurate again. There are already signs of where the journey might be headed. If the past week's growth remains constant, the incidence could already be above the 500 mark in 7 to 10 days. Although such projections are subject to error, it is worth looking at the typical pandemic stocks.
Read
Commented by André Will-Laudien on December 28th, 2021 | 07:15 CET
BioNTech, Pfizer, Defence Therapeutics, Valneva - The Corona year 2022 is coming
The German government has moved its goal of vaccinating 80% of the population against the coronavirus at least once into the new year. The targeted quota is now to be achieved by the end of January, a government spokesman told the press. The background is that only 73.4% of the population has been vaccinated so far, and the missing 5.3 million first-time vaccinations could hardly be achieved by January 7. The interim goal of 30 million vaccinations by the end of the year, on the other hand, will most likely be met after Christmas, government sources say. The general vaccination obligation is to come on the agenda of the Federal Parliament in the first meeting week in the new year. Thus also the year 2022 will stand under the star "Corona". The following shares are part of the orchestra.
Read
Commented by Fabian Lorenz on December 23rd, 2021 | 10:31 CET
+900% with Nvidia still not enough? Are Valneva and BrainChip on the verge of a breakthrough?
2021 was not a good year overall for technology and growth stocks. In particular, companies with a business model not yet profitable had a hard time. They included Peloton and Zoom. One of the top performers in the Nasdaq-100 was the Nvidia share. The chip giant benefits from several trends at once, such as artificial intelligence and the metaverse. If UBS has its way, then 900% price gains in the past three years are not enough. For the analysts of the Swiss bank, the chip stock is the "Top Pick 2022". BrainChip is still a long way from the chip Olympus, but the Company could make a breakthrough in the coming year. The same applies to Valneva, as many are waiting for the dead vaccine, and the stock is still valued relatively low.
Read
Commented by André Will-Laudien on December 21st, 2021 | 13:54 CET
Troilus Gold, Valneva, Moderna, BioNTech - Where will these stocks be in 2022?
The winners in the 2021 investment year have undeniably been the hydrogen, lithium and vaccine stocks. They temporarily gained up to 2,000% but also corrected by more than 50% in some cases. These value developments were not always fundamentally justified. Often the assumption of future achievements was sufficient for a corresponding positive development. In the case of the vaccine manufacturers, the stock market players' fantasies were fulfilled; in the case of hydrogen, this statement was valid at least for a 3-month window at the beginning of the year. Unfortunately, the year was disappointing for most gold explorers, as the precious yellow metal was unable to capitalize on the great uncertainty since the outbreak of the pandemic with a price increase. But this could change in 2022 ad hoc!
Read
Commented by Armin Schulz on December 15th, 2021 | 11:35 CET
Valneva, XPhyto Therapeutics, Pfizer - Corona is far from defeated
In an interview, new Health Minister Karl Lauterbach said, "We will not succeed in defeating Corona completely in the foreseeable period." By period, he probably means his term, which is four years. Thus, the hope that arose in the middle of the year related to a quick end by vaccination seems to have been dashed. The new Omicron variant cannot yet be fully assessed. It is causing uncertainty on the stock markets, which puts renewed pressure on companies that have already suffered from Corona. On the other hand, there are also the profiteers who are fighting Corona. Today we analyze three of these potential profiteers.
Read
Commented by André Will-Laudien on December 9th, 2021 | 13:24 CET
Tilray, Sativa Wellness, NanoRepro, Valneva - The 2022 health winners
The topic of cannabis ran through all the gazettes in 2018 and 2019. The Netherlands, Canada and 9 US states were the well-known pioneers in cannabis legalization at the time. It is now also to come in Germany - at least that is what the coalition agreement of the government parties says. The debate about the legalization of cannabis has been going on worldwide for several years. For Germany, the traffic light coalition wants to legalize the controlled distribution to adults for consumption purposes. In this way, they say, licensing the sale of cannabis would also ensure the protection of minors and prevent the spread of contaminated substances. The industry briefly cheered with share price increases but then returned to normal. We take a look at key industry players.
Read
Commented by Fabian Lorenz on December 8th, 2021 | 14:02 CET
Valneva, Novavax, Manganese X Energy: The new pandemic fighters?
In the fight against the fourth wave of Corona, German industry is now also becoming active. In support of the vaccination campaign, numerous well-known corporations are changing their advertising slogans. Since November 7, more than 150 companies - including BMW, McDonald's, Edeka, Sparkassen, and Volksbanken - have been jointly promoting the corona vaccination. The campaign was developed by the Berlin advertising agency Antoni. In the future, Valneva, Novavax and Manganese X Energy want to contribute to the direct fight against the pandemic. Valneva and Novavax are in a neck-and-neck race for the first inactivated vaccine alternative to the top dogs BioNTech and Moderna. Newcomer Manganese wants to combat Corona with a new air disinfectant and has other arrows in its quiver.
Read
Commented by Stefan Feulner on December 8th, 2021 | 12:53 CET
Tembo Gold, Barrick Gold, Valneva - Sensation on the gold market
Gold mining companies have been in the shadows for months, the gold price is consolidating, and investors are looking for higher-yielding investments such as equities or cryptocurrencies. But behind the scenes, things are bubbling up. Gold producers are sitting on a mountain of cash and looking for interesting takeover targets at current levels. Now, one company has announced a milestone in its history.
Read
Commented by Fabian Lorenz on November 25th, 2021 | 12:44 CET
BioNTech, Valneva, Cardiol Therapeutics: Vaccination boosters also share boosters?
The Corona pandemic has been with us all for a good 18 months now, and there is no end in sight. While the industrialized countries are boosting their vaccines, large parts of the world's population have still not been vaccinated for the first time. That means that shares of manufacturers of vaccines or drugs against COVID-19 will continue to be the focus of investors. Driven by the booster and mandatory vaccination discussions, BioNTech has left the correction behind, and the share is marching towards EUR 300. Drug developer Cardiol Therapeutics should now pick up again after the successful capital increase. In any event, analysts see price potential. Vaccine developer Valneva benefits from the EU order but has not yet recovered from Tuesday's "flash crash".
Read